# Zelfmeting bloeddruk en hypertensie-diagnose bij risicozwangerschap: JAMA BUMP 1

*geplaatst 2022-05-03 · Hypertensie · JAMA · doi 10.1001/jama.2022.4712 · https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/*

JAMA BUMP 1 gerandomiseerde trial naar zelfmeting van bloeddruk voor hypertensie-detectie bij hogere-risicozwangerschap.

## English: Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.

The BUMP 1 trial demonstrated that blood pressure self-monitoring during higher-risk pregnancy does not significantly increase detection of hypertension compared with usual care, though it may improve overall blood pressure awareness.

## Abstract (original, from the publication)

IMPORTANCE: Inadequate management of elevated blood pressure (BP) is a significant contributing factor to maternal deaths. Self-monitoring of BP in the general population has been shown to improve the diagnosis and management of hypertension; however, little is known about its use in pregnancy. OBJECTIVE: To determine whether self-monitoring of BP in higher-risk pregnancies leads to earlier detection of pregnancy hypertension. DESIGN, SETTING, AND PARTICIPANTS: Unblinded, randomized clinical trial that included 2441 pregnant individuals at higher risk of preeclampsia and recruited at a mean of 20 weeks' gestation from 15 hospital maternity units in England between November 2018 and October 2019. Final follow-up was completed in April 2020. INTERVENTIONS: Participating individuals were randomized to either BP self-monitoring with telemonitoring (n = 1223) plus usual care or usual antenatal care alone (n = 1218) without access to telemonitored BP. MAIN OUTCOMES AND MEASURES: The primary outcome was time to first recorded hypertension measured by a health care professional. RESULTS: Among 2441 participants who were randomized (mean [SD] age, 33 [5.6] years; mean gestation, 20 [1.6] weeks), 2346 (96%) completed the trial. The time from randomization to clinic recording of hypertension was not significantly different between individuals in the self-monitoring group (mean [SD], 104.3 [32.6] days) vs in the usual care group (mean [SD], 106.2 [32.0] days) (mean difference, -1.6 days [95% CI, -8.1 to 4.9]; P = .64). Eighteen serious adverse events were reported during the trial with none judged as related to the intervention (12 [1%] in the self-monitoring group vs 6 [0.5%] in the usual care group). CONCLUSIONS AND RELEVANCE: Among pregnant individuals at higher risk of preeclampsia, blood pressure self-monitoring with telemonitoring, compared with usual care, did not lead to significantly earlier clinic-based detection of hypertension. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03334149.

Auteurs: Katherine L Tucker, Sam Mort, Ly-Mee Yu, Helen Campbell, Oliver Rivero-Arias, Hannah M Wilson, Julie Allen, Rebecca Band, Alison Chisholm, Carole Crawford, Greig Dougall, Lazarina Engonidou, Marloes Franssen, Marcus Green, Sheila Greenfield, Lisa Hinton, James Hodgkinson, Layla Lavallee, Paul Leeson, Christine McCourt, Lucy Mackillop, Jane Sandall, Mauro Santos, Lionel Tarassenko, Carmelo Velardo, Lucy Yardley, Lucy C Chappell, Richard J McManus

---
Bron: JAMA, https://doi.org/10.1001/jama.2022.4712. Bijgewerkt 2026-07-03T18:38:51Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.